Highlights Laboratorios Farmaceuticos Rovi, S.A.

Equities

ROVI

ES0157261019

Market Closed - BME Other stock markets 09:05:12 08/05/2024 pm IST			5-day change	1st Jan Change
81.4 ^EUR	-1.69%		-3.44%	+35.22%

02/04	Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment	MT
12/03	Rovi, Partners to Form Entity for Advanced Therapies R&D	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Rovi, Partners to Form Entity for Advanced Therapies R&D	12/03	MT
Rovi explores sale of unit that makes drugs for third parties	07/03	RE
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	26/02	CI
US FDA finds control lapses at Moderna manufacturing plant	16/12	RE
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023	08/11	CI
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	26/23/26	CI
Tranche Update on Laboratorios Farmaceuticos Rovi, S.A.'s Equity Buyback Plan announced on November 3, 2021.	26/23/26	CI
Ex-dividend day for final dividend	03/23/03	FA
Rovi denies being investigated for alleged public subsidies	01/23/01	RE
Laboratorios Farmaceuticos Rovi Denies Receiving Unlawful Public Grants	01/23/01	MT
Tranche Update on Laboratorios Farmaceuticos Rovi, S.A.'s Equity Buyback Plan announced on November 3, 2021.	15/23/15	CI
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	21/23/21	CI
Laboratorios Farmaceuticos Rovi, S.A. Proposes Dividend for the Year 2022	21/23/21	CI
Tranche Update on Laboratorios Farmaceuticos Rovi, S.A.'s Equity Buyback Plan announced on November 3, 2021.	21/23/21	CI
Tranche Update on Laboratorios Farmaceuticos Rovi, S.A.'s Equity Buyback Plan announced on November 3, 2021.	05/22/05	CI
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2022	05/22/05	CI
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	27/22/27	CI
Ex-dividend day for final dividend	05/22/05	FA
Moderna Plans New $521 Million Laboratory In Spain To Boost MRNA Vaccine Production	15/22/15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Laboratorios Farmaceuticos Rovi, S.A.

Equities

ROVI

ES0157261019

Highlights

Filters